Medicamen Biotech Ltd
Incorporated in 1993, Medicamen Biotech Ltd is a research-led pharmaceutical company involved in developing, manufacturing, and marketing generic finished dosage formulations, and Oncology Formulations[1]
- Market Cap ₹ 475 Cr.
- Current Price ₹ 350
- High / Low ₹ 630 / 340
- Stock P/E 53.8
- Book Value ₹ 171
- Dividend Yield 0.29 %
- ROCE 6.55 %
- ROE 4.43 %
- Face Value ₹ 10.0
Pros
Cons
- Promoter holding has decreased over last quarter: -2.70%
- The company has delivered a poor sales growth of 5.24% over past five years.
- Company has a low return on equity of 6.45% over last 3 years.
- Earnings include an other income of Rs.6.12 Cr.
- Dividend payout has been low at 10.5% of profits over last 3 years
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
73 | 78 | 67 | 82 | 112 | 123 | 117 | 110 | 115 | 138 | 172 | 151 | 148 | |
68 | 73 | 62 | 71 | 95 | 105 | 99 | 90 | 91 | 113 | 145 | 135 | 133 | |
Operating Profit | 5 | 5 | 6 | 12 | 17 | 17 | 18 | 20 | 24 | 25 | 27 | 17 | 16 |
OPM % | 7% | 6% | 8% | 14% | 15% | 14% | 15% | 18% | 21% | 18% | 16% | 11% | 11% |
1 | 1 | 1 | 0 | 2 | 4 | 2 | 1 | 2 | 2 | 2 | 6 | 6 | |
Interest | 4 | 4 | 4 | 4 | 3 | 1 | 1 | 2 | 2 | 3 | 6 | 3 | 3 |
Depreciation | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 6 | 6 | 7 | 7 | 7 |
Profit before tax | 0 | 0 | 1 | 6 | 14 | 18 | 17 | 17 | 18 | 17 | 17 | 13 | 12 |
Tax % | 44% | -267% | 32% | 19% | 27% | 31% | 26% | 25% | 18% | 13% | 21% | 26% | |
0 | 0 | 0 | 5 | 10 | 12 | 12 | 12 | 15 | 15 | 13 | 9 | 9 | |
EPS in Rs | 0.10 | 0.46 | 0.48 | 4.91 | 8.89 | 10.28 | 10.04 | 10.22 | 12.20 | 11.86 | 10.46 | 7.43 | 6.87 |
Dividend Payout % | 0% | 0% | 0% | 0% | 12% | 10% | 5% | 10% | 8% | 8% | 10% | 13% |
Compounded Sales Growth | |
---|---|
10 Years: | 7% |
5 Years: | 5% |
3 Years: | 9% |
TTM: | -14% |
Compounded Profit Growth | |
---|---|
10 Years: | 36% |
5 Years: | -5% |
3 Years: | -14% |
TTM: | -21% |
Stock Price CAGR | |
---|---|
10 Years: | 35% |
5 Years: | -3% |
3 Years: | -32% |
1 Year: | -16% |
Return on Equity | |
---|---|
10 Years: | 9% |
5 Years: | 8% |
3 Years: | 6% |
Last Year: | 4% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 9 | 10 | 10 | 11 | 12 | 12 | 12 | 12 | 12 | 13 | 13 | 13 |
Reserves | 8 | 8 | 8 | 16 | 63 | 75 | 110 | 122 | 136 | 181 | 196 | 205 |
15 | 21 | 19 | 18 | 14 | 12 | 11 | 19 | 26 | 26 | 30 | 27 | |
33 | 31 | 23 | 29 | 28 | 38 | 43 | 39 | 52 | 57 | 55 | 48 | |
Total Liabilities | 65 | 69 | 60 | 73 | 118 | 137 | 176 | 192 | 226 | 277 | 294 | 293 |
22 | 20 | 19 | 19 | 25 | 24 | 34 | 90 | 92 | 92 | 91 | 86 | |
CWIP | 1 | 0 | 0 | 0 | 0 | 15 | 40 | 0 | 0 | 0 | 0 | 0 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 4 | 8 | 8 |
42 | 49 | 41 | 54 | 92 | 97 | 100 | 101 | 131 | 180 | 195 | 199 | |
Total Assets | 65 | 69 | 60 | 73 | 118 | 137 | 176 | 192 | 226 | 277 | 294 | 293 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
5 | -3 | 6 | 4 | -5 | 4 | 12 | 13 | 5 | -4 | -0 | -2 | |
-1 | 0 | -1 | -2 | -8 | -15 | -39 | -18 | -8 | -8 | -9 | -2 | |
-4 | 3 | -5 | -1 | 33 | -4 | 21 | 6 | 4 | 28 | 3 | -7 | |
Net Cash Flow | 1 | -0 | 0 | 0 | 20 | -14 | -6 | 1 | 1 | 17 | -6 | -11 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 102 | 124 | 87 | 114 | 126 | 129 | 137 | 165 | 193 | 159 | 102 | 141 |
Inventory Days | 95 | 95 | 95 | 102 | 77 | 67 | 85 | 28 | 188 | 230 | 237 | 274 |
Days Payable | 209 | 187 | 160 | 165 | 118 | 134 | 160 | 161 | 291 | 232 | 152 | 182 |
Cash Conversion Cycle | -13 | 32 | 22 | 51 | 85 | 62 | 62 | 32 | 91 | 157 | 188 | 234 |
Working Capital Days | -32 | 7 | 3 | 34 | 89 | 116 | 139 | 130 | 146 | 151 | 117 | 186 |
ROCE % | 13% | 12% | 12% | 24% | 25% | 20% | 15% | 13% | 12% | 11% | 10% | 7% |
Documents
Announcements
-
Revised Intimation Of Book Closure In Accordance With Regulation 42 Of The SEBI (LODR) Regulations, 2015 (''''Listing Regulations'''')
1d - Book closure Sep 20-26, 2025; 32nd AGM Sep 26, 2025; record date Sep 19; dividend payable by Oct 25, 2025.
-
Intimation Of Book Closure In Accordance With Regulation 42 Of The SEBI (LODR) Regulations, 2015 (''Listing Regulations'')
2d - Book closure Sept 20–26, 2025; 32nd AGM on Sept 26; dividend payable by Oct 25, 2025.
-
Reg. 34 (1) Annual Report.
2d - Annual Report; AGM Sep 26, 2025; Record Date Sep 19; 10% dividend; US FDA ANDA approval; checklist:["Identify key events","Assess materiality and investor impact","Classify priority","Provide concise …
- Announcement under Regulation 30 (LODR)-Newspaper Publication 13 Aug
-
Announcement under Regulation 30 (LODR)-Change in Management
12 Aug - Appointed 2 Independent Directors and promoted Ashwani Kumar Sharma to Executive Director for 5 years.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1][2][3]
MBL, a subsidiary of Shivalik Rasayan Ltd with 41.6% ownership, is an integrated Pharmaceutical and Life Sciences Solution Provider. They manufacture pharmaceutical formulations, primarily focusing on oncology therapeutics and generics, distributed through wholesale drug distributors and sold to institutional segments such as government and semi-government institutions, and hospitals. Their formulations cover beta-lactam, non-beta-lactam, and cephalosporin drugs for overseas and domestic markets.